Zobrazeno 1 - 3
of 3
pro vyhledávání: '"CANVAS Program Collaborative Group"'
Autor:
Melchor Alpizar, Luis Vigil, Hanno Pijl, Kamal Sharma, Christopher J Nolan, Samantha Hocking, Olga Mirolyubova, Yaroslav Malynovsky, Andrzej Madej, Dick De Zeeuw, Vladimir Rafalskiy, ANNA OLIVERAS, SANTIAGO TOFÉ, Francisco J Tinahones, Bruce Neal, John Buse, Jordi Salas-Salvadó, Stefano Genovese, Elena Shutemova
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Neal, B, Perkovic, V, Mahaffey, K W, de Zeeuw, D, Fulcher, G, Erondu, N, Shaw, W, Law, G, Desai, M, Matthews, D R & Gnudi, L 2017, ' Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes ', New England Journal of Medicine, vol. 377, no. 7, pp. 644-657 . https://doi.org/10.1056/NEJMoa1611925
New England Journal of Medicine, 377(7), 644-657. MASSACHUSETTS MEDICAL SOC
Universidad de Barcelona
Neal, B, Perkovic, V, Mahaffey, K W, de Zeeuw, D, Fulcher, G, Erondu, N, Shaw, W, Law, G, Desai, M, Matthews, D R & Gnudi, L 2017, ' Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes ', New England Journal of Medicine, vol. 377, no. 7, pp. 644-657 . https://doi.org/10.1056/NEJMoa1611925
New England Journal of Medicine, 377(7), 644-657. MASSACHUSETTS MEDICAL SOC
BACKGROUND: Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8a27ac48b242dd3e902aa10b55624a
https://doi.org/10.1056/NEJMoa1611925
https://doi.org/10.1056/NEJMoa1611925
Autor:
Mahaffey, KW, Neal, B, Perkovic, V, De Zeeuw, D, Fulcher, G, Erondu, N, Shaw, W, Fabbrini, E, Sun, T, Li, Q, Desai, M, Matthews, DR, CANVAS Program Collaborative Group
Publikováno v:
Circulation
Circulation, 137(4), 323-334. LIPPINCOTT WILLIAMS & WILKINS
Circulation, 137(4), 323-334. LIPPINCOTT WILLIAMS & WILKINS
Supplemental Digital Content is available in the text.
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke i
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c3490fa5784da47ba279d4f2d4db76
https://pubmed.ncbi.nlm.nih.gov/29188808
https://pubmed.ncbi.nlm.nih.gov/29188808
Autor:
Greg Fulcher, Wayne Shaw, Dick de Zeeuw, Gordon Law, Norm Rosenthal, Vlado Perkovic, David R. Matthews, Bruce Neal, Mehul Desai, Ngozi Erondu, Marc K. Walton, Kenneth W. Mahaffey
Publikováno v:
Diabetes obesity & metabolism, 19(7), 926-935. Wiley
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism
Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular Assessment Study (CANVAS) and the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R). A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78fd7f460b50428bf602fb58a9f34afa
https://research.rug.nl/en/publications/46f1e9ef-2099-4eeb-ab60-66ff27b21848
https://research.rug.nl/en/publications/46f1e9ef-2099-4eeb-ab60-66ff27b21848
